Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, announced inducement grants for two newly hired senior executives. The company's Human Capital Management and Compensation Committee has awarded 421,349 time-based restricted stock units (RSUs) each to Jeannine Lombardi, the new Chief Human Resource Officer, and Jonathan Paris, the new Chief Legal Officer.
The RSUs were granted on July 1, 2025, under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan. The vesting schedule includes 25% vesting on July 1, 2026, followed by quarterly installments of 6.25% over the subsequent three years, subject to continued employment.
Definitive Healthcare (Nasdaq: DH), un'azienda di intelligence commerciale nel settore sanitario, ha annunciato l'assegnazione di incentivi per due nuovi dirigenti senior assunti di recente. Il Comitato per la Gestione del Capitale Umano e la Remunerazione dell'azienda ha concesso 421.349 unità azionarie vincolate basate sul tempo (RSU) ciascuno a Jeannine Lombardi, la nuova Chief Human Resource Officer, e a Jonathan Paris, il nuovo Chief Legal Officer.
Le RSU sono state assegnate il 1° luglio 2025, in conformità con la Regola 5635(c)(4) del Nasdaq e il Piano di Incentivi 2023 di Definitive Healthcare. Il piano di maturazione prevede un 25% di maturazione il 1° luglio 2026, seguito da rate trimestrali del 6,25% nei tre anni successivi, subordinatamente alla permanenza in servizio.
Definitive Healthcare (Nasdaq: DH), una empresa de inteligencia comercial en el sector sanitario, anunció concesiones de incentivos para dos altos ejecutivos recientemente contratados. El Comité de Gestión del Capital Humano y Compensación de la empresa otorgó 421,349 unidades restringidas de acciones basadas en tiempo (RSU) a Jeannine Lombardi, la nueva Directora de Recursos Humanos, y a Jonathan Paris, el nuevo Director Legal.
Las RSU fueron concedidas el 1 de julio de 2025, bajo la Regla 5635(c)(4) del Nasdaq y el Plan de Incentivos 2023 de Definitive Healthcare. El calendario de adquisición incluye un 25% de adquisición el 1 de julio de 2026, seguido de cuotas trimestrales del 6.25% durante los siguientes tres años, sujeto a la continuidad del empleo.
Definitive Healthcare (나스ë‹�: DH)ëŠ� ì˜ë£Œ ìƒì—… ì •ë³´ 회사로서, 최근 새로 채용ë� ë‘� ëª…ì˜ ê³ ìœ„ ìž„ì›ì� 위한 ì¸ì„¼í‹°ë¸Œ ë³´ì¡°ê¸ˆì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. 회사ì� ì¸ì ìžë³¸ ê´€ë¦� ë°� ë³´ìƒ ìœ„ì›íšŒëŠ” ì‹ ìž„ ìµœê³ ì¸ì‚¬ ì±…ìž„ìžì¸ Jeannine Lombardi와 ì‹ ìž„ ìµœê³ ë²•ë¥ ì±…ìž„ìžì¸ Jonathan Parisì—게 ê°ê° 421,349ê°œì˜ ì‹œê°„ 기반 ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 부여했습니ë‹�.
ì� RSUëŠ� 2025ë…� 7ì›� 1ì�ì—� 나스ë‹� ìƒìž¥ 규칙 5635(c)(4) ë°� Definitive Healthcareì� 2023ë…� ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ë¶€ì—¬ë˜ì—ˆìŠµë‹ˆë‹¤. ë² ìŠ¤íŒ� ì¼ì •ì€ 2026ë…� 7ì›� 1ì¼ì— 25%ê°€ ë² ìŠ¤íŒ…ë˜ê³�, ì´í›„ 3ë…� ë™ì•ˆ 분기별로 6.25%ì”� ë² ìŠ¤íŒ…ë˜ë©�, ê³„ì† ê³ ìš© ì¡°ê±´ì—� 따릅니다.
Definitive Healthcare (Nasdaq : DH), une entreprise d'intelligence commerciale dans le secteur de la santé, a annoncé des attributions d'incitations pour deux cadres supérieurs nouvellement embauchés. Le comité de gestion du capital humain et de la rémunération de la société a attribué 421 349 unités d'actions restreintes basées sur le temps (RSU) chacune à Jeannine Lombardi, la nouvelle directrice des ressources humaines, et à Jonathan Paris, le nouveau directeur juridique.
Les RSU ont été accordées le 1er juillet 2025, conformément à la règle 5635(c)(4) du Nasdaq et au plan d'incitation 2023 de Definitive Healthcare. Le calendrier d'acquisition prévoit une acquisition de 25 % le 1er juillet 2026, suivie de versements trimestriels de 6,25 % sur les trois années suivantes, sous réserve de la poursuite de l'emploi.
Definitive Healthcare (Nasdaq: DH), ein Unternehmen für kommerzielle Gesundheitsinformationen, gab Anreizzuteilungen für zwei neu eingestellte leitende Führungskräfte bekannt. Der Ausschuss für Human Capital Management und Vergütung des Unternehmens hat jeweils 421.349 zeitbasierte Restricted Stock Units (RSUs) an Jeannine Lombardi, die neue Chief Human Resource Officer, und Jonathan Paris, den neuen Chief Legal Officer, vergeben.
Die RSUs wurden am 1. Juli 2025 gemäß der Nasdaq-Listing-Regel 5635(c)(4) und dem Inducement-Plan 2023 von Definitive Healthcare gewährt. Der Vesting-Plan sieht eine 25%ige Vesting am 1. Juli 2026 vor, gefolgt von vierteljährlichen Raten von 6,25% über die darauffolgenden drei Jahre, vorbehaltlich einer fortgesetzten Anstellung.
- None.
- None.
FRAMINGHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the “Committee�) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Jeannine Lombardi, Definitive Healthcare’s new Chief Human Resource Officer, an inducement award consisting of 421,349 time-based restricted stock units (“RSUs�), and Jonathan Paris, Definitive Healthcare’s new Chief Legal Officer, an inducement award consisting of 421,349 time-based RSUs, each effective July 1, 2025. Each of these awards was individually negotiated and was granted as an inducement material to Ms. Lombardi’s and Mr. Paris’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).
Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Ms. Lombardi’s and Mr. Paris’s RSUs will vest as follows, subject to their continued employment through each such date: (i)
About Definitive Healthcare
At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at .
Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
646-277-1251
Media Contact:
Bethany Swackhamer
